FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
July 06, 2021 14:34 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses...
HealthCare Partners Expands Relationship with AposHealth® to Bring an Innovative, Non-Invasive Treatment for Knee Osteoarthritis to Members Through a New Delivery Model
February 02, 2021 09:00 ET
|
AposHealth®
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- HealthCare Partners (HCP) today announced an expansion of its partnership with AposHealth® to bring an innovative, non-invasive treatment for knee...
AposHealth Awarded Research Grant to Support Rebuilding Efforts in the United Kingdom
January 04, 2021 15:24 ET
|
AposTherapy®
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- AposHealth®, a global leader in the identification and treatment of gait-related conditions known for its clinically proven, non-invasive treatment for knee...
Global Viscosupplementation Market Is Expected to Reach USD 7.06 Billion by 2027 : Fior Markets
September 17, 2020 07:00 ET
|
Fior Markets
Newark, NJ, Sept. 17, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global viscosupplementation market is expected to grow from USD 3.72 billion in 2019 and to reach USD...
Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
May 22, 2020 09:00 ET
|
Samumed, LLC.
SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...
Research Published in The Journal of the American Medical Association (JAMA) Shows Knee Osteoarthritis Patients Treated with AposTherapy® Experienced Significant Pain Reduction
May 18, 2020 10:40 ET
|
AposTherapy
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Researchers from Boston University School of Medicine, the University of Bern Switzerland, and the University of Toronto studied two hundred twenty...
Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial
June 19, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group).Most...
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow Lesions
May 03, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 03, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Initiates Phase 3 Study of AXS-02 for Knee Osteoarthritis Associated with Bone Marrow Lesions
March 28, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
First Patient Enrolled in the COAST-1 StudyNon-Opioid, Oral, Targeted, Potentially First-in-Class Mechanism for PainNovel Biomarker-Based Approach for the Treatment of Knee Osteoarthritis...
Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis ReJoin® Stem Cell Therapy
December 22, 2015 09:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...